Sort
261,768 grants matching “gene therapy”
Stromal Regulation of Bone Metastasis
$975,515Raghu Kalluri · University Of Tx Md Anderson Can Ctr · U54 · FY2014 · CA
3/7-PsycheMERGE: Advancing Precision Psychiatry
$975,499Roseann Elizabeth Peterson · Suny Downstate Medical Center · R01 · FY2024 · MH
The Laboratory of Stem Cell Biology
$975,474Mahendra Rao · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2012 · AR
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy
$975,387Brian C Gilger · Bedrock Therapeutics, Inc. · R42 · FY2024 · EY
"Discovery and Development of Anti-Diabetic Drugs."
$975,307Gerard M Housey · Housey Pharmaceutical Research Lab · R44 · FY2012 · DK
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
$975,215Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2023 · DK
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
$975,215Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2024 · DK
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer
$975,131Alex Toker · Beth Israel Deaconess Medical Center · R35 · FY2023 · CA
Human Pluripotent Stem Cell Differentiation with Defined O2 & Protein Engagement
$975,069Clark K Colton · Massachusetts Institute Of Technology · RC1 · FY2010 · DE
Molecular profile of proviral reservoirs in HIV-infected drug users
$975,058Xu Yu · Massachusetts General Hospital · R33 · FY2024 · DA
Preclinical Development of Oxy200 for the Treatment of Osteoporosis
$975,009Frank Stappenbeck · Max Biopharma, Inc. · R44 · FY2019 · AG
Preclinical Development of Oxy200 for the Treatment of Osteoporosis
$975,009Frank Stappenbeck · Max Biopharma, Inc. · R44 · FY2018 · AG
A blueprint for neutrophil heterogeneity and reprogramming in cancer
$975,000Chengcheng Jin · University Of Pennsylvania · DP2 · FY2025 · CA
Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma
$975,000Michael Jackson · Sanford Burnham Prebys Medical Discovery Institute · R61 · FY2020 · NS
Interaction between nuclear epigenetic and metabolic pathways in cancer
$975,000Shelley L Berger · University Of Pennsylvania · R35 · FY2022 · CA
Metabolic Influences on Complex Tumor Neighborhoods
$975,000M. Celeste Simon · University Of Pennsylvania · R35 · FY2025 · CA
CENTER FOR DIGESTIVE AND LIVER DISEASES
$975,000University Of Pennsylvania · P30 · FY2000 · DK
Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma
$974,959Yen Tun Wang · Curebiotech, Inc. · R44 · FY2020 · CA
Gene regulatory elements, networks, and mechanisms
$974,955Raja Jothi · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate Cancer
$974,889Lawrence H Schwartz · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
$974,850Joel S. Bader · Johns Hopkins University · U01 · FY2018 · CA
Role of Memory T Cell Dynamics in SIV Infection
$974,775Louis J. Picker · Oregon Health & Science University · R37 · FY2017 · AI
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
$974,750Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2021 · AI
Integrins and Ocular Angiogenesis
$974,701Martin Friedlander · Scripps Research Institute, The · R01 · FY2009 · EY
Novel Adipose Targeted Gene Therapy for Lipodystrophy
$974,604Al Hawkins · Zvelt Therapeutics Inc. · R42 · FY2025 · DK